Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Century Therapeutics (IPSC)
NASDAQ:IPSC
RESEARCH TOOLSreports
IPSC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.68 - $5.51
Previous CloseN/A
Volume712.78K
Average Volume (3M)493.26K
Market Cap
$64.06M
Enterprise Value$1.33M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.48
Next Earnings
Mar 13, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding85,029,045
10 Day Avg. Volume361,415
30 Day Avg. Volume493,262
Standard Deviation0.29
R-Squared0.08
Alpha-0.06
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)23.86
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.12
Enterprise Value/Ebitda-0.01
Forecast
1Y Price Target
$7.33Price Target Upside851.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Century Therapeutics News
PremiumCompany Announcements
Century Therapeutics Unveils Advances in Cell Therapies
PremiumCompany Announcements
Century Therapeutics Faces Termination of BMS Agreement
PremiumCompany Announcements
Century Therapeutics Reports Q3 Results & Strategic Updates---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsCentury Therapeutics is launching a trial of its CNTY-101 therapy in autoimmune diseases, which is seen as a validation of their approach.
Technology PlatformThe therapeutic potential and dosing flexibility of Century Therapeutics' Allo-Evasion technology promises superior clinical outcomes with CNTY-101 in autoimmune diseases.
Therapeutic PotentialCNTY-101 showed an encouraging and clear dose response with five responses in six patients with relapsed or refractory B-cell lymphoma.
Bears Say
Clinical Data RiskRisks include delays in advancing candidates from the pipeline into clinical trials and potential failure to generate favorable clinical data.
Collaboration TerminationBMS' decision to discontinue their collaboration agreement with Century is disappointing and attributed to 'an internal corporate portfolio prioritization process.'
Regulatory RiskThere is a risk of not securing regulatory approval for therapies, particularly CNTY-101, which could impact the company's future.
---
Ownership Overview
3.40% Insiders
6.11% Mutual Funds
23.80% Other Institutional Investors
61.61% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IPSC FAQ
What was Century Therapeutics’s price range in the past 12 months?
Century Therapeutics lowest stock price was $0.68 and its highest was $5.51 in the past 12 months.
What is Century Therapeutics’s market cap?
Century Therapeutics’s market cap is $64.06M.
When is Century Therapeutics’s upcoming earnings report date?
Century Therapeutics’s upcoming earnings report date is Mar 13, 2025 which is in 24 days.
How were Century Therapeutics’s earnings last quarter?
Century Therapeutics released its earnings results on Nov 05, 2024. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.451 by $0.081.
Is Century Therapeutics overvalued?
According to Wall Street analysts Century Therapeutics’s price is currently Undervalued.
Does Century Therapeutics pay dividends?
Century Therapeutics does not currently pay dividends.
What is Century Therapeutics’s EPS estimate?
Century Therapeutics’s EPS estimate is -0.41.
How many shares outstanding does Century Therapeutics have?
Century Therapeutics has 85,029,045 shares outstanding.
What happened to Century Therapeutics’s price movement after its last earnings report?
Century Therapeutics reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.451. Following the earnings report the stock price went up 5.556%.
Which hedge fund is a major shareholder of Century Therapeutics?
Currently, no hedge funds are holding shares in IPSC
---
Century Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.33 (851.95% Upside)
$7.33 (851.95% Upside)
Blogger Sentiment
Bullish
IPSC Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $1.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 10.2%
Last 30 Days ▲ 10.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.76%
12-Months-Change
Fundamentals
Return on Equity
-62.61%
Trailing 12-Months
Asset Growth
-2.25%
Trailing 12-Months
Company Description
Century Therapeutics
Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a significant unmet medical need. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies.
---
IPSC Stock 12 Month Forecast
Average Price Target
$7.33
▲(851.95% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering IPSC
1 Year
1 Year Success Rate
2/19 ratings generated profit
1 Year Average Return
-42.90%
reiterated a buy rating 26 days ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 10.53% of your transactions generating a profit, with an average return of -42.90% per trade.
---